Advertisement

Tumor Biology

, Volume 36, Issue 7, pp 5497–5503 | Cite as

A novel recombinant protein of ephrinA1–PE38/GM-CSF activate dendritic cells vaccine in rats with glioma

  • Ming Li
  • Bin Wang
  • Zhonghua Wu
  • Jiadong Zhang
  • Xiwen Shi
  • Wenlan Cheng
  • Shuangyin Han
Research Article

Abstract

Dendritic cells loaded with tumor-associated antigens can effectively stimulate the antitumor immune response of cytotoxic T lymphocytes in the body, which facilitates the development of novel and effective treatments for cancer. In this study, the adenovirus-mediated ephrinA1–PE38/GM-CSF was successfully constructed using the overlap extension method, and verified with sequencing analysis. HEK293 cells were infected with the adenovirus and the cellular expression of ephrinA1–PE38/GM-CSF was measured with an enzyme-linked immunosorbent assay. The recombinant adenovirus was then delivered into the tumor-bearing rats and the results showed that such treatment significantly reduced the volumes of gliomas and improved the survival of the transplanted rats. The results from immunohistochemistry and flow cytometry suggested that this immunomodulatory agent cause activation of dendritic cells. The findings that ephrinA1–PE38/GM-CSF had a high efficacy in the activation of the dendritic cells would facilitate the development of in vivo dendritic-cell vaccines for the treatment of gliomas in rats. Our new method of DC vaccine production induces not only a specific local antitumor immune response but also a systemic immunotherapeutic effect. In addition, this method completely circumvents the risk of contamination related to the in vitro culture of DCs, thus greatly improving the safety and feasibility of clinical application of the DC vaccines in glioma.

Keywords

Dendritic cells EphrinA1 GM-CSF Glioma 

Notes

Acknowledgments

The authors thank Dr. Tian-fang Li (Rush University Medical Center) for critical reading and helpful discussion. This work was supported by National Natural Science Foundation of China (no. 81372405).

Conflicts of interest

None

References

  1. 1.
    Folkman J. Angiogenesis in cancer vascular rheumatoid and other disease. Nat Med. 1995;1(1):27–31.CrossRefPubMedGoogle Scholar
  2. 2.
    Kerbel RS. A cancer therapy resistant to resistance. Nature. 1997;390(27):335–6.CrossRefPubMedGoogle Scholar
  3. 3.
    Gille J. Antiangiogenic cancer therapies get their act together: current developments and future prospects of growth factor- and growth factor receptor-targeted approaches. Exp Dermatol. 2006;15(3):175–86.CrossRefPubMedGoogle Scholar
  4. 4.
    Juratli TA, Schackert G, Krex D. Current status of local therapy in malignant gliomas—a clinical review of three selected approaches. Pharmacol Ther. 2013;139(3):341–58.CrossRefPubMedGoogle Scholar
  5. 5.
    Fan M, Liu Y, Xia F, Wang Z, Huang Y, Li J, et al. Increased expression of EphA2 and E-N cadherin switch in primary hepatocellular carcinoma. Tumori. 2013;99(6):689–96.PubMedGoogle Scholar
  6. 6.
    Russo S, Incerti M, Tognolini M, Castelli R, Pala D, Hassan-Mohamed I, et al. Synthesis and structure-activity relationships of amino acid conjugates of cholanic acid as antagonists of the EphA2 receptor. Molecules. 2013;18(10):13043–60.CrossRefPubMedGoogle Scholar
  7. 7.
    Chen H, Yuan B, Zheng Z, Liu Z, Wang S, Liu Y. A novel vaccine containing EphA2 epitope and LIGHT plasmid induces robust cellular immunity against glioma U251 cells. Cell Immunol. 2011;272(1):102–6.CrossRefPubMedGoogle Scholar
  8. 8.
    Alho I, Costa L, Bicho M, Coelho C. Low molecular weight protein tyrosine phosphatase isoforms regulate breast cancer cells migration through a RhoA dependent mechanism. PLoS One. 2013;8(9):e76307.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Strimpakos A, Pentheroudakis G, Kotoula V, De Roock W, Kouvatseas G. The prognostic role of ephrin A2 and endothelial growth factor receptor pathway mediators in patients with advanced colorectal cancer treated with cetuximab. Clin Colorectal Cancer. 2013;12(4):267–74.CrossRefPubMedGoogle Scholar
  10. 10.
    Hegde M, Corder A, Chow KK, Mukherjee M, Ashoori A, Kew Y. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol Ther. 2013;21(11):2087–101.CrossRefPubMedCentralGoogle Scholar
  11. 11.
    Mantripragada K, Khurshid H. Targeting genomic alterations in squamous cell lung cancer. Front Oncol. 2013;3(8):195.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Lee HY, Mohammed KA, Goldberg EP, Nasreen N. Arginine-conjugated albumin microspheres inhibits proliferation and migration in lung cancer cells. Am J Cancer Res. 2013;3(3):266–77.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Lu XS, Sun W, Ge CY, Zhang WZ, Fan YZ. Contribution of the PI3K/MMPs/Ln-5γ2 and EphA2/FAK/Paxillin signaling pathways to tumor growth and vasculogenic mimicry of gallbladder carcinomas. Int J Oncol. 2013;42(6):2103–15.PubMedGoogle Scholar
  14. 14.
    Sun XL, Xu ZM, Ke YQ, Hu CC, Wang SY, Ling GQ, et al. Molecular targeting of malignant glioma cells with an EphA2-specific immunotoxin delivered by human bone marrow-derived mesenchymal stem cells. Cancer Lett. 2011;312(2):168–77.CrossRefPubMedGoogle Scholar
  15. 15.
    Ullrich E, Bonmort M, Mignot G, Chaput N, Taieb J, Menard C, et al. Therapy-induced tumor immunosurveillance involves IFN-producing killer dendritic cells. Cancer Res. 2007;67(3):851–3.CrossRefPubMedGoogle Scholar
  16. 16.
    Kyte JA, Mu L, Aamdal S, Kvalheim G. Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther. 2006;13(10):905–18.CrossRefPubMedGoogle Scholar
  17. 17.
    Hu CC, Ke YQ, Sun XL, Jiang XD, Xu RX, Lv J, et al. Human mesenchymal stem cells-like cells as cellular vehicles for delivery of immunotoxin in vitro. Biotechnol Lett. 2009;31(2):181–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Hu CC, Ji HM, Chen SL, Zhang HW, Wang BQ, Zhou LY, et al. Investigation of a plasmid containing a novel immunotoxin VEGF165-PE38 gene for antiangiogenic therapy in a malignant glioma model. Int J Cancer. 2010;127(9):2222–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Li M, Liu J, Zhang SZ, Zhou Y, Guo YW, Chen Q, et al. Cellular immunologic response to primary cryoablation of C6 gliomas in rats. Technol Cancer Res Treat. 2011;10(1):95–100.PubMedGoogle Scholar
  20. 20.
    Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol. 2011;29(3):330–6.CrossRefPubMedGoogle Scholar
  21. 21.
    Holtl L, Rieser C, Papesh C, Ramoner R, Herold M, Klocker H, et al. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol. 1999;161(3):777–82.CrossRefPubMedGoogle Scholar
  22. 22.
    Wang H, Su X, Zhang P, Liang J, Wei H, et al. Recombinant heat shock protein 65 carrying PADRE and HBV epitopes activates dendritic cells and elicits HBV-specific CTL responses. Vaccine. 2011;29(12):2328–35.CrossRefPubMedGoogle Scholar
  23. 23.
    Debenedette MA, Calderhead DM, Tcherepanova IY, Nicolette CA, Healey DG. Potency of mature CD40L RNA electroporated dendritic cells correlates with IL-12 secretion by tracking multifunctional CD8(+)/CD28(+) cytotoxic T-cell responses in vitro. J Immunother. 2011;34(1):45–57.CrossRefPubMedGoogle Scholar
  24. 24.
    Gong J, Avigan D, Chen D, Wu Z, Koido S, Kashiwaba M, et al. Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc Natl Acad Sci U S A. 2000;97(6):2715–8.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Szanto A, Balint BL, Nagy ZS, Barta E, Dezso B, Pap A, et al. STAT6 transcription factor is a facilitator of the nuclear receptor PPARgamma-regulated gene expression in macrophages and dendritic cells. Immunity. 2010;33(5):699–712.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Liu Y, Zhang W, Chan T, Saxena A, Xiang J. Engineered fusion hybrid vaccine of IL-4 gene-modified myeloma and relative mature dendritic cells enhances antitumor immunity. Leuk Res. 2002;26(8):757–63.CrossRefPubMedGoogle Scholar
  27. 27.
    Wertel I, Bednarek W, Stachowicz N, Rogala E, Nowicka A, Kotarski J. Phenotype of dendritic cells generated from peripheral blood monocytes of patients with ovarian cancer. Transplant Proc. 2010;42(8):3301–5.CrossRefPubMedGoogle Scholar
  28. 28.
    Martins A, Han J, Kim SO. The multifaceted effects of granulocyte colony-stimulating factor in immunomodulation and potential roles in intestinal immune homeostasis. IUBMB Life. 2010;62(8):611–7.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Lee JH, Roh MS, Lee YK, Kim MK, Han JY. Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model. Cancer Gene Ther. 2010;17(2):73–9.CrossRefPubMedGoogle Scholar
  30. 30.
    Si T, Guo Z, Hao X. Combined cryoablation and GM-CSF treatment for metastatic hormone refractory prostate cancer. J Immunother. 2009;32(1):86–91.CrossRefPubMedGoogle Scholar
  31. 31.
    Ward JE, Mcneel DG. GVAX: an allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancer. Expert Opin Biol Ther. 2007;7(12):1893–902.CrossRefPubMedGoogle Scholar
  32. 32.
    Nemunaitis J. Vaccines in cancer: GVAX, a GM-CSF gene vaccine. Expert Rev Vaccines. 2005;4(3):259–74.CrossRefPubMedGoogle Scholar
  33. 33.
    Harzstark AL, Small EJ. Sipuleucel-T for the treatment of prostate cancer. Drugs Today (Barc). 2008;44(4):271–8.CrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Ming Li
    • 1
  • Bin Wang
    • 1
  • Zhonghua Wu
    • 1
  • Jiadong Zhang
    • 1
  • Xiwen Shi
    • 1
  • Wenlan Cheng
    • 1
  • Shuangyin Han
    • 2
  1. 1.Department of NeurosurgeryZhengzhou University People’s HospitalZhengzhou CityChina
  2. 2.Central Research LabZhengzhou University People’s HospitalZhengzhou CityChina

Personalised recommendations